- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S1639
| Related Targets | HDAC Caspase Proteasome Secretase MMP HCV Protease Cysteine Protease DPP Tyrosinase Serine Protease |
|---|---|
| Other HIV Protease Inhibitors | Pepstatin A Limonin Temsavir (BMS-626529) Rosamultin Bevirimat Dextran sulfate sodium (DSS) Mericitabine NBD-556 GS-6207 Azvudine |
|
In vitro |
Ethanol : 101 mg/mL
DMSO
: 30 mg/mL
(59.33 mM)
Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 505.63 | Formula | C25H35N3O6S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 161814-49-9 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | 141W94, VX-478, KVX-478 | Smiles | CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N | ||
| Targets/IC50/Ki |
PXR
HIV protease
14.6 ng/mL
|
|---|---|
| In vitro |
Amprenavir (VX-478) promotes the specific interactions between the nuclear receptor pregnane X receptor (PXR) and the coactivators SRC-1 and PBP. It is docked into the high-resolution crystal structure of human PXR in complex with SR12813. This compound occupies all four subpockets, and its hydroxyl group forms a hydrogen bond with Ser247, which is located in the connection region of PXR, to help to position the drug in the optimal orientation inside the receptor. It forms direct contacts with one residue on αAF of the PXR activation function-2 (AF-2) surface, Phe429, which may stabilize the active AF-2 conformation of the receptor and contribute to the agonist activity on PXR. It induces the expression of bona fide PXR target genes involved in phase I (CYP3A4), phase II (UGT1A1), and phase III (MDR1) metabolism in both HepaRG cells and LS180 cells.
|
| In vivo |
Amprenavir (VX-478) increases atherogenic LDL cholesterol fractions in WT mice, but not in PXR−/− mice. It stimulates expression of known PXR target genes, including CYP3A11, glutathione transferase A1, and MDR1a, in the intestine of WT mice but not in PXR−/− mice. This compound-mediated PXR activation stimulates the expression of both LipF and LipA in the intestine of WT mice, but not in PXR−/− mice, indicating a possible role of intestinal PXR in mediating dietary lipid breakdown and absorption in mammals.
|
References |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01209065 | Completed | Infections Human Immunodeficiency Virus and Herpesviridae |
ViiV Healthcare|GlaxoSmithKline |
September 2010 | Phase 1 |
| NCT00817765 | Completed | HIV Infection|Fungal Infection |
Radboud University Medical Center|GlaxoSmithKline |
January 2009 | Phase 1 |
| NCT00802074 | Completed | Healthy |
Garden State Infectious Disease Associates PA|GlaxoSmithKline |
December 2008 | Not Applicable |
| NCT00764465 | Completed | Healthy |
Garden State Infectious Disease Associates PA|GlaxoSmithKline |
October 2008 | Phase 2 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.